尽管股票出现小幅下跌, 但Sun Pharma在印度推出了治疗牛皮的新药ILUMYA. Sun Pharma launches ILUMYA for psoriasis in India, offering new treatment despite minor stock dip.

在印度,Sun制药工业公司发起了ILUMYA(Tildrakizumab),这是对中度至重度白板微粒丝虫病的生物治疗。 Sun Pharmaceutical Industries has launched ILUMYA (tildrakizumab), a biologic treatment for moderate to severe plaque psoriasis, in India. 该药物已在35个国家提供,为慢性免疫机能丧失症提供有效和持续的皮肤清理,影响全球人口的2-3%和印度人口的0.44%至2.8%。 The drug, already available in 35 countries, offers effective and sustained skin clearance for the chronic autoimmune condition, which affects 2-3% of the global population and 0.44% to 2.8% in India. 发射为病人提供了一种新的治疗选择,尽管Sun Pharma的股份在宣布后下跌0.73%至BSE的1,817.90卢比。 The launch provides a new treatment option for patients, though Sun Pharma’s shares dipped 0.73% to Rs 1,817.90 on the BSE following the announcement.